Filing Flows › CorMedix (CRMD) › R&D spending
CorMedix (CRMD) R&D spending by quarter
CorMedix's R&D spending was $6.7M in Q2 2026 (second quarter 2026), -7% from Q1 2026. Over the last 7 quarters it ranged from $1.7M (Q4 2024) to $8.6M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $6.7M | -7% | +174% |
| Q1 2026 | $7.2M | -16% | +126% |
| Q4 2025 | $8.6M | +69% | +398% |
| Q3 2025 | $5.1M | +109% | — |
| Q2 2025 | $2.4M | -24% | — |
| Q1 2025 | $3.2M | +85% | — |
| Q4 2024 | $1.7M | — | — |
Q2 2026 at a glance
CorMedix, Q2 2026: revenue $102M (+156% year over year), operating margin 42.1%, net earnings $26.0M, operating cash flow $86.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is CorMedix's R&D spending?
CorMedix's R&D spending was $6.7M in Q2 2026 (second quarter 2026), -7% from Q1 2026.
How has CorMedix's R&D spending changed?
Over the last 7 quarters it ranged from $1.7M (Q4 2024) to $8.6M (Q4 2025).